Protagonist Therapeutics
PTGX
188 hedge funds and large institutions have $2.05B invested in Protagonist Therapeutics in 2024 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 63 increasing their positions, 68 reducing their positions, and 26 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
18% more capital invested
Capital invested by funds: $1.73B → $2.05B (+$312M)
15% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 26
2% more funds holding
Funds holding: 185 → 188 (+3)
7% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 68
2.2% less ownership
Funds ownership: 102.91% → 100.71% (-2.2%)
87% less call options, than puts
Call options by funds: $956K | Put options by funds: $7.56M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$26.8M |
| 2 |
JFG
Jefferies Financial Group
New York
|
+$25.2M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$24M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$11.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$44.9M |
| 2 |
State Street
Boston,
Massachusetts
|
-$34.9M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$12.8M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$11.9M |
| 5 |
CAC
Cowen and Company
New York
|
-$11M |
PTGX Hedge Fund Activity: Q2 2024 in Review
188 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2024, worth a combined $2.05B — up 18% from $1.73B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new PTGX positions and 26 closed out — a net gain of 4 holders — while 63 added to existing stakes and 68 trimmed.
The largest buyer was Millennium Management, adding an estimated $26.8M. The largest seller was Morgan Stanley, cutting an estimated $44.9M.
- 188 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2024, up from 185 in Q1 2024.
- Funds reported $2.05B of Protagonist Therapeutics stock for Q2 2024, up 18% quarter-over-quarter.
- 30 funds opened new Protagonist Therapeutics positions in Q2 2024 and 26 closed out, a net change of +4 holders.
- The largest Protagonist Therapeutics buyer in Q2 2024 was Millennium Management, an estimated $26.8M added.
- The largest Protagonist Therapeutics seller in Q2 2024 was Morgan Stanley, an estimated $44.9M sold.
Based on aggregated 13F filings for Q2 2024.